Your session is about to expire
← Back to Search
Pembrolizumab + Blinatumomab for Acute Lymphoblastic Leukemia
Study Summary
This trial is testing the side effects and effectiveness of two cancer drugs, pembrolizumab and blinatumomab, in treating patients with acute lymphoblastic leukemia that has returned or is resistant to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function, measured by creatinine levels, is within the normal range.My cancer can be seen in my bone marrow or outside of it and can be measured and biopsied again.My blood clotting time is normal or slightly above, unless I'm on blood thinners.I do not have a severe illness that could affect my safety or how my body processes pembrolizumab.My heart pumps blood well.I have been diagnosed with mature B-cell ALL or lymphoid blast crisis CML.I have a history of cancer that is not related to lymphoid tissue, with exceptions.I have had lung inflammation not caused by an infection.My cancer did not respond to initial treatment or has come back after treatment.I stopped all cancer treatments at least 1 week ago or waited for 5 half-lives of the treatment.I am on maintenance therapy medications.My blood clotting time is normal or slightly above, unless I'm on blood thinners.I have recently undergone chemotherapy, targeted therapy, or radiation.I have recently received a live vaccine.My leukemia is CD19-positive B-cell ALL.I received chemotherapy directly into my spinal canal no more than 7 days before starting pembrolizumab.My side effects from previous cancer treatments are mild or gone.I have stopped taking biologic medications for the required time.I have had a bone marrow transplant from another person.I am fully active or can carry out light work.I have had myelodysplastic syndrome or an organ transplant.I have been treated with specific medications before.I have a liver condition.I have active or symptomatic brain or spinal cord problems.I am on medication for an autoimmune disease.
- Group 1: Treatment (pembrolizumab, blinatumomab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions can be alleviated via Pembrolizumab administration?
"Pembrolizumab is a reliable therapeutic option for treating unresectable melanoma. Additionally, this medication can be used to treat or manage microsatellite instability high, refractory b-cell precursor acute lymphoblastic leukemia and other conditions with an elevated risk of recurrence."
Is this research endeavor still accepting new participants?
"Affirmative. The clinicaltrials.gov website corroborates that this medical trial is actively searching for participants, with the initial post being made on August 2nd 2019 and its most recent update occurring on May 19th 2022. 36 individuals are expected to be recruited from a single centre."
Has Pembrolizumab been explored for medical purposes in prior research?
"According to the available data, there are currently 1006 clinical trials concerning Pembrolizumab in action around the globe. Of these studies, 131 are Phase 3 and Houston, Texas holds a significant number of them. Moreover, 38104 sites across the world are studying this medication."
How many participants are being enrolled in the research protocol?
"Affirmative. According to clinicaltrials.gov, this trial is currently enrolling; it was first published on August 2nd 2019 and the most recent edit happened on May 19th 2022. 36 participants are needed at a single medical centre."
Share this study with friends
Copy Link
Messenger